Sign In
Buy SAVA
$1.96
+0 (+0%)
At Close: Jun 03, 2026
Top Penny Stocks To Buy? 3 Former Stocks Under $5 To Watch Now
10:44am, Tuesday, 21'st Dec 2021
Are these former penny stocks on your list to buy right now or is the rally over? The post Top Penny Stocks To Buy?
SAVA Stock: The Social Media Chatter That Has Cassava Sciences Trending Today
10:33am, Tuesday, 21'st Dec 2021
Cassava Sciences (SAVA) stock is getting some extra attention today from traders on social media and we've got all the details. The post SAVA Stock: The Social Media Chatter That Has Cassava Sciences
Cassava Stock Surges as Social Media Buzz Intensifies
10:14am, Tuesday, 21'st Dec 2021
The shares of Cassava Sciences Inc (NASDAQ:SAVA) are surging before the bell, last seen up 33.6% at $49.13, as the heavily shorted stock gains popularity on social media this morning.
Cassava Sciences Stock (SAVA): Why The Price Surged
10:01am, Tuesday, 21'st Dec 2021
The shares of Cassava Sciences, Inc. (NASDAQ: SAVA) were halted this morning. This is why it happened.
3 Stocks That Turned $200,000 Into $1 Million (or More) in 2021
10:51am, Saturday, 18'th Dec 2021 The Motley Fool
These highly popular companies delivered gains ranging from 558% to 996% this year.
7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts
01:51pm, Tuesday, 07'th Dec 2021
These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months. The post 7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts appeared
Interview With Cassava Sciences' CEO Remi Barbier - Data Integrity, Elon Musk, And The Haters
05:02pm, Monday, 06'th Dec 2021
We have a wide-ranging phone interview with Cassava Sciences' CEO Remi Barbier. He addresses crazy accusations and data safeguards.
Is Longeveron a Good Biotech Stock to Buy?
10:31am, Sunday, 05'th Dec 2021 The Motley Fool
Stem cell therapies are back in vogue, at least for this Miami-based biotechnology company.
Should Investors Worry About the Federal Investigation of Cassava?
11:55am, Thursday, 02'nd Dec 2021 The Motley Fool
The investigation really isn't the underlying concern.
Cassava Sciences Teaches Us 4 Lessons To Find The Next Big Thing
09:21pm, Wednesday, 01'st Dec 2021
Cassava Sciences has been one of 2021's best stocks. We can learn some things from Cassava to help us find the next great biotech or growth & innovation stock.
Is the Options Market Predicting a Spike in Cassava Sciences (SAVA) Stock?
02:34pm, Friday, 26'th Nov 2021 Zacks Investment Research
Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Cassava Sciences (SAVA) Stock?
10:43am, Friday, 26'th Nov 2021
Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
Cassava Sciences Just Returned to the Buy Zone
11:00am, Monday, 22'nd Nov 2021
There's no need to panic about SAVA stock, as Cassava Sciences just launched an important study focused on treating Alzheimer's disease. The post Cassava Sciences Just Returned to the Buy Zone appeare
Will Cassava Sciences Stock Continue To See Lower Levels?
08:45am, Friday, 19'th Nov 2021
The stock price of Cassava Sciences plunged 23% yesterday after a report that the U.S. SEC is investigating the company over allegations of data manipulation for its experimental Alzheimer's treatment
Biogen's (BIIB) Aducanumab Gets CHMP's Negative Trend Vote
03:36pm, Thursday, 18'th Nov 2021 Zacks Investment Research
Biogen's (BIIB) regulatory application seeking approval for its Alzheimer's drug, Aduhelm, in Europe hits setback as it receives negative trend vote from the CHMP.
